Printer Friendly

LASERSIGHT BEGINS HUMAN TRIALS AT MOUNT SINAI MEDICAL CENTER IN NEW YORK FOR ITS REFRACTIVE LASER EYE SURGERY

 NEW YORK, Oct. 6 /PRNewswire/ -- LaserSight Inc. (NASDAQ: LASE) announced today that FDA Phase I human trials of its Compak-200 mini-excimer laser for myopic (nearsightedness) photorefractive keratectomy (PRK) have begun here at the Mount Sinai Medical Center. Dr. Penny Asbell, the Principal Investigator, is performing the PRK surgeries.
 "This is an innovative step in the next generation of excimer lasers and will spread worldwide the availability for doctors and patients," said Asbell, associate professor at Mount Sinai Medical Center well- known for her work in corneal surgery.
 "We are excited about working with Mount Sinai on this very important next step for LaserSight," said Dr. J.T. Lin, chief executive officer of LaserSight. "LaserSight considers this a major milestone toward the clinical trials of our advanced PRK mini-excimer laser."
 The company also announced that during 1994 it expects to open up four more clinical sites in the United States for additional PRK human trials and 10 more PRK Centers in European countries.
 Based in Orlando, Fla., LaserSight is at the cutting edge of new technology specializing in compact, light-weight, low-cost refractive laser systems for non-invasive eye surgery.
 -0- ? 10/6/93
 /CONTACT: Carl R. Thompson of Carl Thompson Associates, 303-494-5472; or J.T. Lin of LaserSight, 407-382-2702/
 (LASE)


CO: LaserSight Inc. ST: New York, Florida IN: MTC SU:

MC -- DV003 -- 9254 10/06/93 10:19 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 6, 1993
Words:227
Previous Article:ASARCO BEGINS SOIL SAMPLING IN GLOBEVILLE
Next Article:IVI PUBLISHING, INC. OFFERS 1,150,000 SHARES OF COMMON STOCK
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters